ストックスクリーナーアプリを入手
1.64
0.61%
-0.01
アフターアワーズ：
1.60
-0.04
-2.44%
前日終値:
$1.65
開ける：
$1.69
24時間の取引高:
884.10K
Relative Volume:
0.32
時価総額：
$116.79M
収益：
$391.70K
当期純損益:
$-52.34M
株価収益率:
-2.1867
EPS:
-0.75
ネットキャッシュフロー:
$-45.92M
1週間 パフォーマンス:
-1.80%
1か月 パフォーマンス:
+24.24%
6か月 パフォーマンス:
+466.89%
1年 パフォーマンス:
+54.72%
1日の値動き範囲:
$1.61
$1.71
1週間の範囲:
$1.54
$1.71
52週間の値動き範囲:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
名前
Ovid Therapeutics Inc
セクター
電話
212-776-4381
住所
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
OVID を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.64 | 117.50M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-11 | 開始されました | Roth Capital | Buy |
| 2025-11-17 | 開始されました | Leerink Partners | Outperform |
| 2025-10-09 | 開始されました | Oppenheimer | Outperform |
| 2025-08-08 | 再開されました | B. Riley Securities | Buy |
| 2024-06-18 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 開始されました | B. Riley Securities | Buy |
| 2024-04-29 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-05 | 開始されました | Wedbush | Outperform |
| 2023-12-21 | 開始されました | BTIG Research | Buy |
| 2023-10-13 | 開始されました | Oppenheimer | Outperform |
| 2021-04-20 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-02 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-04-20 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Ovid Therapeutics Inc (OVID) 最新ニュース
Aug Big Picture: How analysts rate Ovid Therapeutics Inc stock todayWeekly Loss Report & Technical Confirmation Alerts - moha.gov.vn
Janus Henderson Group PLC Acquires Significant Stake in Ovid Therapeutics Inc - GuruFocus
Roth Capital Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat
Ovid Therapeutics shareholders approve increase in authorized shares and related proposals - Investing.com
Ovid Therapeutics shareholders approve increase in authorized shares and related proposals By Investing.com - Investing.com South Africa
Ovid Therapeutics Stockholders Approve Key Proposals - TipRanks
Roth Capital Initiates Coverage of Ovid Therapeutics (OVID) with Buy Recommendation - Nasdaq
Roth/MKM initiates Ovid Therapeutics stock with Buy rating on epilepsy drug - Investing.com Canada
OVID: Roth Capital Initiates Coverage with a "Buy" Rating at $3. - GuruFocus
What analysts say about Ovid Therapeutics Inc stockTrading Volume Surges & Capitalize On Fast Trends - earlytimes.in
Will Ovid Therapeutics Inc. stock deliver long term returns - Newser
Will Ovid Therapeutics Inc. (1OT) stock see valuation expansionEarnings Recap Report & Low Risk High Win Rate Stock Picks - Newser
Will Ovid Therapeutics Inc. (1OT) stock gain from lower interest ratesPortfolio Performance Summary & Weekly Market Pulse Alerts - Newser
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Will Ovid Therapeutics Inc. stock gain from strong economyDividend Hike & Precise Entry and Exit Recommendations - Newser
Will Ovid Therapeutics Inc. (1OT) stock benefit from sector leadershipJuly 2025 Opening Moves & Verified Chart Pattern Signals - Newser
Is Ovid Therapeutics Inc. (1OT) stock attractive for growth fundsJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
Ovid Therapeutics appoints Petra Kaufmann as chief medical officer By Investing.com - Investing.com Nigeria
Ovid Therapeutics Names Petra Kaufmann Chief Medical Officer - marketscreener.com
Ovid Therapeutics appoints Petra Kaufmann as chief medical officer - Investing.com
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer - Enidnews.com
How Ovid Therapeutics Inc. (1OT) stock correlates with oil marketsProduct Launch & Real-Time Chart Pattern Alerts - Newser
Is Ovid Therapeutics Inc. (1OT) stock dividend growth reliableMarket Trend Review & Free Real-Time Volume Trigger Notifications - Newser
IPO Launch: Is Ovid Therapeutics Inc stock positioned well for digital economyWeekly Gains Summary & Weekly Stock Performance Updates - moha.gov.vn
November 2025's Top Penny Stock Opportunities - simplywall.st
HC Wainwright Has Negative Estimate for OVID FY2025 Earnings - MarketBeat
What analysts say about Ovid Therapeutics Inc 1OT stockVolume Profile Analysis & Explosive Profit Growth - earlytimes.in
Ovid Therapeutics (OVID): HC Wainwright Raises Price Target to $2.00 | OVID Stock News - GuruFocus
HC Wainwright & Co. Maintains Ovid Therapeutics (OVID) Buy Recommendation - Nasdaq
Ovid CEO Meg Alexander Takes The Helm In Time To Harvest Growing Blooms - Citeline News & Insights
Is Ovid Therapeutics Inc. stock overvalued by current metricsJuly 2025 Highlights & Real-Time Market Sentiment Alerts - newser.com
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Equities Analysts Issue Forecasts for OVID Q4 Earnings - MarketBeat
Visual trend scoring systems applied to Ovid Therapeutics Inc.Earnings Risk Summary & Detailed Earnings Play Alerts - newser.com
What consensus target says about Ovid Therapeutics Inc. (1OT) stock2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Is Ovid Therapeutics Inc. stock cheap at current valuation2025 Market Outlook & Expert Curated Trade Setups - newser.com
Regression analysis insights on Ovid Therapeutics Inc. performanceDollar Strength & High Yield Equity Trading Tips - newser.com
Ovid Therapeutics Reports Q3 2025 Financial Results - MSN
Combining machine learning predictions for Ovid Therapeutics Inc. - newser.com
Long term hold vs stop loss in Ovid Therapeutics Inc.2025 Short Interest & Community Trade Idea Sharing - newser.com
Ovid Therapeutics Inc (OVID) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):